

28 **Abstract**

29 Neurodivergent (ND) individuals (e.g., Autistic people) are more likely to experience health
30 problems that are characterised by central sensitisation'. Recent research suggests that a
31 so-called 'Long-COVID' syndrome might also be explained by a heightened response to
32 internal physiological stimuli, much like in myalgic encephalomyelitis/chronic fatigue
33 syndrome (ME/CFS). Using a standardised assessment tool, we examined whether traits
34 associated with Autism would predict long-term COVID-19 symptoms in 267 Healthcare
35 Workers (HCW).. Higher autistic traits predicted COVID-19 symptoms that lasting more than
36 12 weeks regardless of formal autism diagnosis. A personality measure also showed that
37 negative affect was associated with experiencing COVID-19 symptoms for 4-12 weeks,
38 though the direction of causality in this case is uncertain. Limitations of the present study are
39 1) the retrospective nature of COVID-19 symptom reporting; 2) likely self-selection bias
40 given the high number of HCWs who reported long-term COVID-19 symptoms; and 3) the
41 gender-bias towards females in our sample.

42

43

44 **Introduction**

45 Since the onset of the global COVID-19 pandemic in 2020, researchers have sought to
46 understand the long-term consequences of SARS-CoV-2 infection. Guidelines have been
47 published in attempts to define a 'Long-COVID' syndrome, suggesting that the duration of
48 COVID-19 symptoms can be categorised as either acute COVID-19 Symptoms (AC) lasting
49 up to 4wks post-infection; ongoing symptomatic COVID-19 (OSC) with symptoms up to
50 12wks; or post-COVID-19 syndrome (PCS); when symptoms span beyond 12 weeks – more
51 commonly known as Long-COVID^[1]. Long-term symptoms can include physiological
52 sequelae, typically shortness of breath (SOB), cough, headache, myalgia/arthralgia, fatigue
53 and/or psychological outcomes such as cognitive impairment, memory loss, anxiety and
54 depression^[2]. Recent studies suggest that some individuals are more prone to developing
55 long-term symptoms of COVID-19, with females, smokers and those with pre-existing co-
56 morbidities being the most at-risk^[3-8]. Furthermore, symptoms of Long-COVID have been
57 likened to those that characterise myalgic encephalomyelitis/chronic fatigue syndrome
58 (ME/CFS) - a chronic multi-system condition, that has been found to be triggered by
59 infectious diseases such as Influenza and Coronaviruses^[8,9].

60

61 While the mechanisms underlying ME/CFS are not fully understood, a key theory is that of
62 'Central Sensitization'(CS), whereby the nervous system has an amplified response to
63 certain stimuli. For example, a heightened reaction to nociceptive input may lead to
64 hyperalgesia and thus a heightened experience of pain^[10]. This theory has been applied to
65 certain groups, where an amplified internal response to external stimuli is commonplace,
66 such as neurodivergent (ND) people (e.g. Autistic people). Accordingly, a recent study found
67 that a large proportion of autistic individuals met the diagnostic criteria for ME/CFS, as well
68 other conditions characterised by CS, including fibromyalgia and irritable bowel syndrome
69 (IBS). Sixty-percent of autistic participants also scored at or above the clinical cut-off on a
70 screening tool for CS^[10]. Considering this evidence, we aimed to examine whether autistic

71 individuals, and those with higher self-reported autistic characteristics are also at greater risk
72 of developing long-term symptoms of COVID-19. As some evidence suggests that Type D
73 traits, including negative affect and social inhibition, are more common in those with
74 conditions such as ME/CFS and fibromyalgia,^[11] this measure was included to control for
75 these as a possible confounder. In the present study, we therefore surveyed a group of
76 healthcare workers (HCWs) and asked them about their experience of ongoing COVID-19
77 symptoms. Our main aim was to see whether longer-term COVID-19 symptoms were more
78 common in those who scored higher on a measure of autistic characteristics in ND and Type
79 D Personality (TDP).

80

81 **Method**

82

83 *Ethics Statement*

84

85 All participants gave their written informed consent, and Cambridge East Research Ethics
86 Committee approved this study (Ethics Ref: 20/EE/0161), which was performed in
87 accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Data
88 was collected between August and November 2022. Authors were blinded to identifiable
89 participant information.

90

91 *Participants*

92 In this observational survey-based study, HCWs were recruited from three Northeast
93 England hospitals and formed an opportunistic sample. HCWs were invited via email to
94 complete an online survey, which was advertised to all HCWs using the weekly
95 communications service.

96

97 *Materials and Procedure*

98 The anonymous survey explored HCWs' experience of COVID-19 symptoms, including
99 nature, severity and duration. Prior COVID-19 history was defined as previous positive self-
100 reported polymerase chain reaction (PCR), antibody (AB) and/or lateral flow test (LFT).
101 HCWs indicated which COVID-19 symptoms they experienced from the following list: chest
102 pain; memory/concentration problems; cough; diarrhoea; fatigue; fever/chills; headache; joint
103 pain; loss taste/sell; muscle pain; nausea/vomiting; SOB; sore throat; swollen lymph nodes.
104 Severity was ranked as 'Mild' (no interference with daily activities); 'Moderate' (some
105 interference); 'Severe' (prevented daily activities); 'Very Severe' (required hospital
106 visit/hospitalisation). Symptoms duration was categorised according to previously cited
107 guidelines^[1], as AC, OCS, or PCS. Vaccination history was also recorded. HCWs were
108 invited to self-declare whether they were neurodivergent. Autistic traits were assessed using
109 the Ritvo Autism & Asperger Diagnostic Scale (RAADS-14)^[12]. TDP was explored using the
110 DS14, a psychometric tool that captures negative affectivity and social inhibition^[13]. Effects of
111 age and gender were also considered within our analyses.

112

113 *Statistical Analysis*

114 Statistical analysis was conducted using JASPv0.16.3.0^[14]. Categorical outcomes were
115 examined with chi-square tests and multinomial regression. Continuous outcomes were
116 investigated using ANOVA. An alpha level of .05 indicating significance was used
117 throughout.

118

119 **Results**

120 Of the 267 respondents (35 M, 226 F, 6 other; mean age 48.3yrs), 153 (57%) reported one
121 episode of COVID-19, 100 (37%) reported two episodes, and 14 (5%) recalled three or
122 more, which had been diagnosed on positive PCR (208, 78%), LFT (158, 41%) or AB test
123 (33, 12%) with 111 positive on both PCR and LFT. 212 (79.5%) received three doses of
124 vaccine, 23 (8.5%) more than three doses, 24 (9%) had two doses, 3 (1%) one dose and 3
125 (1%) none. Two (1%) declined to give vaccine information. Regarding COVID-19 symptoms

126 124 (46%) resolved within 4wks (AC), 64 (24%) between 4-12wks (OCS) and 79 (30%) had
127 symptoms >12wks (PCS).

128

129 Thirty-eight (14%) self-declared being ND (16 autistic; 14 attention deficit hyperactivity
130 disorder; 21 others including dyslexia, dyscalculia, dyspraxia; 12 with multiple conditions),
131 whilst 7 (3%) declined to answer. There was no significant association between either OCS
132 or PCS and self-declared ND status ($X^2(2)=2.59$, $p=.27$). Based on the RAADS cut-off of 14,
133 83 (31%) scored above this threshold and there was a significant association of being above
134 threshold with likelihood of experiencing OCS or PCS ($X^2(2)=10.01$, $p=.007$).

135

136 There was a significant association between number of COVID-19 episodes and symptom
137 duration ($X^2(4)=13.57$, $p=.009$) with 2 episodes being associated with PCS. Increased
138 symptom number during first episode was reporting by people going on to develop either
139 OCS or PSC (7.5(2.9) or 8.3(3.0) vs 5.1(2.9) symptoms; $F(2,272)=34.46$, $p<.001$), with the
140 increased occurrence of every symptom being associated with OCS or PCS except fever
141 and sore throat. Those reporting PCS also reported greater severity of symptoms during the
142 first episode compared to those with OCS, or those whose symptoms resolved ($X^2(6)=43.90$,
143 $p<.001$). There was no association of reported first episode symptom severity with ND
144 status ($X^2(6)=2.58$, $p=.86$).

145

146 Examining the subscales of the RAADS, there was no difference between COVID-19
147 duration groups on mentalising ($F(2,259)=2.37$, $p=.10$) or social anxiety ($F(2,259)=2.5$,
148 $p=0.08$), but a significant difference in sensory reactivity ($F(2,259)=4.85$, $p=.009$), with post-
149 hoc testing showing that there was a significant difference between the AC and PCS (1.62
150 (2.49) vs 3.81 (3.02)). There was no overall difference in DS14 between the COVID-19

151 duration groups ($F(2,259)=2.41, p=.09$). Negative affectivity was significantly higher in those
152 experiencing OCS ($F(2,272)=3.72, p=.03$), but not those with PCS. See Table 1 for HCW
153 characteristics.

154 - Insert Table 1 –

155

156 A multinomial logistic model was constructed with three levels of outcome being symptom
157 duration. Age and gender were included in the model at step one, and the two TDP
158 subscales and three RAADS subscales entered at a second step. The second step resulted
159 in a significant improvement in model fit ($X^2(10)=22.75, p=.012$). Only the DS14 subscale for
160 negative affectivity was a significant predictor of OCS versus AC. PCS was significantly
161 predicted by the RAADS sensory reactivity subscale as well as increasing age and being
162 female. Coefficients are given in Table 2. Repeating the analysis with OCS symptoms as the
163 baseline, none of the factors significantly differentiate that from the PCS group.

164

165 A similar model revealed that after controlling for age, gender, RAADS sensory reactivity and
166 TDP negative reactivity, OCS was significantly predicted by the presence of SOB (O.R. 6.14
167 [2.64–14.29], $p<.001$). PCS was predicted by the occurrence of concentration or memory
168 problems (O.R. 5.59 [2.28–13.72], $p<.001$), during first episode. Fever during the first
169 episode was associated with lower likelihood of OCS (O.R. 0.37 [0.15–0.90], $p=.03$ or LC
170 O.R. 0.21 [0.08–0.56], $p=.002$).

171

172 - Insert Table 2 –

173

174 **Discussion**

175

176 Conditions characterised by CS, such as ME/CFS, are more common in those with ASD^[11].
177 PCS, where symptoms of SARS-CoV-2 infection last beyond 12 weeks^[1], has been likened
178 to ME/CFS^[8,9]. We explored whether neurodivergent HCWs were more likely to experience
179 prolonged symptoms of COVID-19 and whether TDP traits are a risk factor for PCS.

180

181 In our sample 30% described having COVID-19 symptoms beyond 12wks post-infection.
182 This is alarmingly high, given the extent to which ongoing COVID-19 symptoms can impact
183 daily life. Loss of earnings, dependency on caregivers, and an inability to perform everyday
184 activities are just a few of the consequences of PCS cited in the recent literature^[15]. Some of
185 the previously highlighted risk factors for prolonged COVID-19 symptoms were replicated in
186 the present study, with females and older individuals being more at risk of PCS. Having had
187 multiple episodes of COVID-19 was also associated with longer length of symptoms, and
188 increased symptom number in the first episode was associated with OCS/PCS.

189 Regarding Type D Personality, TDP traits overall were not different across the AC/OCS/PCS
190 groups. Importantly, the confounder of negative affect was only marginally associated with
191 OCS, and not at all with PCS. The direction of causality in this finding must be carefully
192 considered, as it is unclear as to whether the presence of OCS might have led to greater
193 negative affect, or if those with naturally greater negative affectivity were more likely to have
194 had symptoms for longer because they perhaps did not take the actions necessary to
195 accelerate their recovery (e.g., returning to regular activities).

196

197 Interestingly only 13% of HCW self-declared that they were neurodivergent, whereas 31% of
198 the group scored above threshold on the RAADS. This is consistent with evidence to
199 suggest that people with fewer stereotypical characteristics frequently go un-diagnosed^[16].
200 Analyses also revealed that PCS was predicted by the 'sensory reactivity' subscale of the
201 RAADS, suggesting that HCWs who scored highly on this element were more likely to have

202 prolonged symptoms. This finding fits with the theory that a CS mechanism may underlie
203 conditions such as ME/CFS^[9].

204

205 The main limitations of the present study are the likelihood of self-selection bias given that
206 30% of HWCS had experienced PCS, that we relied on HCWs to recall symptoms of COVID-
207 19 retrospectively, and that the sample was largely comprised of female participants (85%).
208 Nevertheless, our work provides preliminary evidence to support the sensory reactivity
209 element of neurodivergence as a risk factor for developing Long-COVID. This finding has
210 implications for the provision of treatment services in at-risk groups^[16], particularly
211 psychological interventions, which autistic individuals often find difficult to access^[18,19].

212

213 **Conclusion**

214 Our key findings are first, more HCWs scored above threshold for neurodivergence than
215 those who self-declared having been diagnosed neurodivergent; second, there was no
216 association between OCS/PCS and HCWs self-declared neurodivergent status; third, TDP
217 did not differ or predict OCS/PCS, but the negative affectivity subscale was a relatively
218 weak predictor of being in the OCS group; and finally, scoring above or below the RAADS
219 threshold was predictive of PCS, with the sensory reactivity subscale (in addition to age and
220 female sex) predicting COVID-19 symptoms lasting >12 weeks.

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235 **Contributors**

236 RKR/JR/DRC/AP conceived the study and DRC is chief investigator of the CHOIS study.

237 RKR acted as site principal investigator. RKR/JR/DRC contributed to the study protocol,

238 design, and data collection. JR did the statistical analysis. RKR/JR/DRC prepared the

239 manuscript. All authors critically reviewed and approved the final version.

240

241 **Financial Disclosure**

242 The CHOIS study was supported by the North East and North Cumbria Academic Health

243 Sciences Network (AHSN; fund awarded to co-author DRC). The funders had no role in

244 study design, data collection and analysis, decision to publish, or preparation of the

245 manuscript.

246

247 **Competing Interests**

248 The authors have declared that no competing interests exist.

249

250 **Acknowledgements**

251 We would like to thank the CHOIS research team, John Rouse and the North East and North

252 Cumbria NIHR for assistance with the survey.

253

254 **Data Availability**

255 All data will be made available upon request.

256

257 **References**

- 258 1. National Institute of Clinical Excellence (NICE), the Scottish Intercollegiate
259 Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP).
260 *NICE 'long COVID' guideline*. 2021. [https://www.guidelines.co.uk/infection/nice-long-](https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article)
261 [covid-guideline/455728.article](https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article) (accessed April 11, 2023).
- 262 2. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS et al.
263 Symptoms, complications and management of long COVID: a review. *J R Soc Med*.
264 2021;114(9):428-442. <https://doi.org/10.1177/01410768211032850>.
- 265 3. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T et al. Symptoms
266 and risk factors for long COVID in non-hospitalized adults. *Nat Med*.
267 2022;28(8):1706-1714. <https://doi.org/10.1038/s41591-022-01909-w>.
- 268 4. Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR. Prior COVID-19 infection is
269 associated with increased Adverse Events (AEs) after the first, but not the second,
270 dose of the BNT162b2/Pfizer vaccine. *Vaccine*. 2022;40(3):418-423.
271 <https://doi.org/10.1016/j.vaccine.2021.11.090>.
- 272 5. Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but
273 not Long-COVID, is associated with increased adverse events following
274 BNT162b2/Pfizer vaccination. *J Infect*. 2021 ;83(3):381-412.
275 <https://doi.org/10.1016/j.jinf.2021.05.035>.
- 276 6. Raw RK, Rees J, Chadwick DR. Increased adverse events following third dose of
277 BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent
278 influenza vaccine. *PLOS Glob Public Health*. 2023;3(2):e0001053.
279 <https://doi.org/10.1371/journal.pgph.0001053>.
- 280 7. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk
281 factors, and treatments. *Infect Dis (Lond)*. 2021;53(10):737-754.
282 <https://doi.org/10.1080/23744235.2021.1924397>

- 283 8. Astin R, Banerjee A, Baker MR, Dani M, Ford E et al. Long COVID: mechanisms, risk
284 factors and recovery. *Exp Physiol.* 2023;108(1):12-27.
285 <https://doi.org/10.1113/EP090802>.
- 286 9. Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-
287 infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review.
288 *Ther Adv Infect Dis.* 2021;8:20499361211009385.
289 <https://doi.org/10.1177/20499361211009385>.
- 290 10. Grant S, Norton S, Weiland RF, Scheeren AM, Begeer S, Hoekstra RA. Autism and
291 chronic ill health: an observational study of symptoms and diagnoses of central
292 sensitivity syndromes in autistic adults. *Mol Autism.* 2022;13(1):7.
293 <https://doi.org/10.1186/s13229-022-00486-6>.
- 294 11. Ablin JN, Zohar AH, Zaraya-Blum R, Buskila D. Distinctive personality profiles of
295 fibromyalgia and chronic fatigue syndrome patients. *PeerJ.* 2016;4:e2421.
296 <https://doi.org/10.7717/peerj.2421>.
- 297 12. Eriksson JM, Andersen LM, Bejerot S. RAADS-14 Screen: validity of a screening tool
298 for autism spectrum disorder in an adult psychiatric population. *Mol Autism.*
299 2013;4(1):49. <https://doi.org/10.1186/2040-2392-4-49>.
- 300 13. Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and
301 Type D personality. *Psychosom Med.* 2005, 67 (1): 89-97.
302 <https://doi.org/10.1097/01.psy.0000149256.81953.49>.
- 303 14. JASP Team (2022). *JASP* (Version 0.16.3) [Computer software].
- 304 15. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, Alwan NA.
305 Characteristics and impact of Long Covid: Findings from an online survey. *PLoS*
306 *One.* 2022;17(3):e0264331. <https://doi.org/10.1371/journal.pone.0264331>.
- 307 16. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. *Eur J*
308 *Pharmacol.* 2020;889:173644. <https://doi.org/10.1016/j.ejphar.2020.173644>.
- 309 17. Morales Hidalgo P, Voltas Moreso N, Canals Sans J. Autism spectrum disorder
310 prevalence and associated sociodemographic factors in the school population:

311 EPINED study. *Autism*. 2021;25(7):1999-2011.

312 <https://doi.org/10.1177/13623613211007717>.

313 18. Camm-Crosbie L, Bradley L, Shaw R, Baron-Cohen S, Cassidy S. 'People like me
314 don't get support': Autistic adults' experiences of support and treatment for mental
315 health difficulties, self-injury and suicidality. *Autism*. 2019;23(6):1431-1441.

316 <https://doi.org/10.1177/1362361318816053>.

317 19. Adams, D., Young, K. A Systematic Review of the Perceived Barriers and Facilitators
318 to Accessing Psychological Treatment for Mental Health Problems in Individuals on
319 the Autism Spectrum. *Rev J Autism Dev Disord*. 2021;8:436–453.

320 <https://doi.org/10.1007/s40489-020-00226-7>.

321

322

323 **List of Abbreviations**

324

- 325 • **AB:** Antibody
- 326 • **AC:** Acute COVID-19
- 327 • **CS:** Central Sensitisation
- 328 • **DS14:** Type D Personality Scale
- 329 • **HCWs:** Healthcare Workers
- 330 • **IBS:** Irritable Bowel Syndrome
- 331 • **LFT:** Lateral Flow Test
- 332 • **ME/CFS:** Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- 333 • **ND:** Neurodivergent/Neurodivergence
- 334 • **OSC:** Ongoing Symptomatic COVID-19
- 335 • **PCR:** Polymerase Chain Reaction
- 336 • **PCS:** Post-COVID-19 Syndrome
- 337 • **RAADS:** Ritvo Autism & Asperger Diagnostic Scale
- 338 • **SOB:** Shortness of Breath
- 339 • **TDP:** Type D Personality

340

341 **Tables and Table Captions**

342

	AC n= 124	OCS n =64	PCS n =79
Age (years)	47.1 (11.6)	49.2 (10.0)	49.4 (10.8)
Mdn first episode symptoms	5	8	8
RAADS total	8.40 (9.71)	11.77 (9.40)	10.92 (10.0)
RAADS Mentalising	4.33 (5.25)	6.00 (5.36)	4.95 (5.63)
RAADS Social Anxiety	2.45 (3.15)	3.38 (3.27)	3.17 (3.26)
RAADS Sensory Reactivity	1.62 (2.61)	2.39 (2.49)	2.81 (3.02)
DS14 Total	23.34 (11.46)	27.06 (10.33)	25.09 (10.55)
DS14 Negative Affectivity	11.59 (6.94)	14.33 (6.20)	12.54 (6.29)
DS14 Social Inhibition	11.65 (5.84)	12.73 (5.40)	12.54 (5.90)

343

344 **Table 1.** *Characteristics of the three patient groups showing mean (SD) for age, totals and*
345 *subscale totals for the RAADS and DS14 and median number of symptoms reported during*
346 *first COVID-19 episode.*

347

	Estimate (S.E.)	Odds Ratio (95% C.I.)	p
OCS v AC			
Intercept	-2.99 (1.03)		
Age	0.03 (0.02)	1.03 (0.99 – 1.06)	.07
Sex	M: -0.37 (1.34)	0.69 (0.05 – 9.63)	.79
	F-M 0.62 (0.51)	1.86 (0.68 – 5.08)	.23
DS14 Negative Affectivity	0.07 (0.03)	1.07 (1.01 – 1.15)	.04
DS14 Social Inhibition	-0.08 (0.05)	0.92 (0.84 – 1.01)	.92
RAADS mentalising	-0.003 (0.05)	1.00 (0.91 – 1.10)	.95
RAADS Social Anxiety	0.13 (0.08)	1.14 (0.98 – 1.33)	.09
RAADS Sensory Reactivity	0.09 (0.08)	1.10 (0.93 – 1.29)	.27
PCS v AC			
Intercept	-3.10 (1.02)		
Age	0.03 (0.02)	1.03 (1.00 – 1.06)	.04
Sex	M: -0.05 (1.31)	0.96 (0.07 – 12.50)	.97
	F-M: 1.13 (0.54)	3.09 (1.07 – 8.88)	.04
DS14 Negative Affectivity	0.01 (0.03)	1.01 (0.95 – 1.08)	.70
DS14 Social Inhibition	-0.04 (0.05)	0.96 (0.88 – 1.05)	.40
RAADS mentalising	-0.07 (0.05)	0.93 (0.85 – 1.02)	.12
RAADS Social Anxiety	0.13 (0.08)	1.14 (0.98 – 1.32)	.09
RAADS Sensory reactivity	0.22 (0.08)	1.25 (1.07 – 1.46)	.004

348

349 **Table 2.** Coefficients from multinomial logistic regression predicting occurrence of OCS or

350 PCS against baseline AC from the three RAADS and two DS14 subscales.

351